Matrix metalloproteinase-2 in oncostatin M-induced sarcomere degeneration in cardiomyocytes (original) (raw)

The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: A possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart

Johann Wojta

Journal of Molecular and Cellular Cardiology, 2005

View PDFchevron_right

The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure

Ayse Vera Cetinkaya

International Journal of Molecular Sciences

View PDFchevron_right

Cardiac Restricted Overexpression of Membrane Type-1 Matrix Metalloproteinase Causes Adverse Myocardial Remodeling following Myocardial Infarction

Lawrence W Dobrucki

Journal of Biological Chemistry, 2010

View PDFchevron_right

Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction

Marina Bergman

American Journal of Physiology-Heart and Circulatory Physiology, 2006

View PDFchevron_right

Myocardial matrix metalloproteinase-2: inside out and upside down

Francisco Chong Villarreal

Journal of molecular and cellular cardiology, 2014

View PDFchevron_right

Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling

C. McTiernan

Cardiovascular Research, 2000

View PDFchevron_right

Human cardiac fibroblast extracellular matrix remodeling: dual effects of tissue inhibitor of metalloproteinase-2

Guoqi Teng

Cardiovascular Pathology, 2014

View PDFchevron_right

Matrix metalloproteinases and their function in myocardium

Karel Kotaska

Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2005

View PDFchevron_right

Matrix Metalloproteinases Repress Hypertrophic Growth in Cardiac Myocytes

Péter Bencsik

Cardiovascular Drugs and Therapy

View PDFchevron_right

Cardiac-Restricted Overexpression of Membrane Type1 Matrix Metalloproteinase in Mice Effects on Myocardial Remodeling With Aging

Christy Beck

View PDFchevron_right

Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart

Wang Wang

2000

View PDFchevron_right

Paradigmatic identification of MMP-2 and MT1-MMP activation systems in cardiac fibroblasts cultured as a monolayer

Martin Elliott, Chun Guo

Journal of Cellular Biochemistry, 2005

View PDFchevron_right

Type I Collagen-induced MMP-2 Activation Coincides with Up-regulation of Membrane Type 1-Matrix Metalloproteinase and TIMP-2 in Cardiac Fibroblasts

Chun Guo

View PDFchevron_right

MMP induction and inhibition in myocardial infarction

Merry Lindsey

Heart failure reviews, 2004

View PDFchevron_right

Inhibition of MMP-2 expression affects metabolic enzyme expression levels: Proteomic analysis of rat cardiomyocytes

Francisco Cayabyab

Journal of Proteomics, 2014

View PDFchevron_right

Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte

Hernando León

British Journal of Pharmacology, 2008

View PDFchevron_right

Titin is a Target of Matrix Metalloproteinase-2: Implications in Myocardial Ischemia/Reperfusion Injury

Henk Granzier

Circulation, 2010

View PDFchevron_right

Role of extracellular matrix metalloproteinases in cardiac remodelling

Hanumanth Reddy

Heart Failure Reviews, 1996

View PDFchevron_right

Matrix Metalloproteinase Inhibition After Myocardial Infarction

Jack Cleutjens

Circulation Research, 2001

View PDFchevron_right

Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy

Gonzalo De La Morena

American Heart Journal, 2008

View PDFchevron_right

M atrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction

Wilma Suarez-pinzon, Xiaonan Gao

2000

View PDFchevron_right

Disruption of the myocardial extracellular matrix leads to cardiac dysfunction

Erik Young

Journal of Clinical Investigation, 2000

View PDFchevron_right

Matrix Metalloproteinase Inhibition After Myocardial Infarction: A New Approach to Prevent Heart Failure?

Jack Cleutjens

Circulation Research, 2001

View PDFchevron_right

MMP-2 is localized to the mitochondria-associated membrane of the heart

Woo Jung Cho

American Journal of Physiology-Heart and Circulatory Physiology, 2013

View PDFchevron_right

Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy

Heinz-peter Schultheiss, Sophie Van Linthout

Basic Research in Cardiology, 2008

View PDFchevron_right

Selective Matrix Metalloproteinase Inhibition Reduces Left Ventricular Remodeling but Does Not Inhibit Angiogenesis After Myocardial Infarction

Jamie Crawford

Circulation, 2002

View PDFchevron_right

Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells

you charles

View PDFchevron_right

Matrix Metalloproteinases in Myocardial Infarction and Heart Failure

Cesar A Meschiari

Progress in molecular biology and translational science, 2017

View PDFchevron_right